Thousands more UK black men to be invited for prostate cancer screening
The UK Health Secretary has announced an expansion of the Transform trial to include more black men for prostate cancer screening. This decision follows a recommendation from the UK National Screening Committee (UKNSC) against population-wide testing, citing potential harm outweighing benefits for the general population.

Briefing Summary
AI-generatedThe UK Health Secretary has announced an expansion of the Transform trial to include more black men for prostate cancer screening. This decision follows a recommendation from the UK National Screening Committee (UKNSC) against population-wide testing, citing potential harm outweighing benefits for the general population. Instead, a few thousand high-risk men with BRCA2 gene mutations and a family history of certain cancers will be screened every two years. The expanded Transform trial will invite black men aged 45-74 in the UK who haven't had recent PSA tests or MRI scans. This £20 million investment aims to improve prostate cancer research and treatment, though some campaigners criticize the decision as perpetuating existing inequalities. The program is expected to roll out in 2027.
Article analysis
Model · rule-basedKey claims
5 extractedNick Jones accused the government of accepting a recommendation that 'entrenches' injustices and is a 'dereliction of duty that will cost lives'.
Prostate cancer is the most common form of the disease in the UK, with over 64,000 men diagnosed annually.
Men with BRCA2 genetic mutations and a family history of certain cancers will be tested every two years between 45 and 61.
The UK national screening committee (UKNSC) recommended against screening all men using the PSA blood test, stating it was 'likely to cause more harm than good'.
Thousands more black men will be invited to take part in a prostate cancer screening trial.